0ACH Stock Chart & Stats
€24.46
-€1.10(-4.15%)
At close: 4:00 PM EDT
€24.46
-€1.10(-4.15%)
Day’s Range― - ―
52-Week Range€19.69 - €39.38
Previous CloseN/A
Volume7.32K
Average Volume (3M)3.24K
Market Cap
€802.47M
Enterprise Value€731.65
Total Cash (Recent Filing)€84.82M
Total Debt (Recent Filing)€57.41M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Dec 08, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding35,924,610
10 Day Avg. Volume1,808
30 Day Avg. Volume3,239
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)264.15
Price to Sales (P/S)41.46
P/FCF Ratio-30.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€38.00Price Target Upside55.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€47.65M
Bulls Say, Bears Say
Bulls Say
UZEDY Royalty GrowthRapid growth in partner-reported UZEDY sales is translating into higher royalties, strengthening MedinCell’s recurring revenue base. Continued adoption and the expanded bipolar-I label can support durable commercial momentum while reducing reliance on development-stage milestone payments.
Olanzapine LAI Regulatory ProgressAcceptance of the olanzapine LAI NDA materially advances a second potential royalty-generating product toward commercialization. The subcutaneous formulation’s record of more than 4,000 clinical injections without observed PDSS events may provide differentiation if approval and launch timelines are achieved.
Expanding Partnered PipelineA broad formulation-stage pipeline creates multiple opportunities to convert BEPO technology into future partnerships, milestones and royalties. Partner-funded work also validates external demand for the platform and can broaden growth beyond the current UZEDY and olanzapine programs.
Bears Say
Persistent Losses And Declining RevenueThe latest year shows that revenue growth has not yet translated into operating leverage or sustainable profitability. Declining annual revenue alongside materially wider losses leaves the business dependent on future product ramps, milestones and royalties to support its investment-heavy model.
Cash Burn And Thin EquitySignificant cash consumption reduces financial flexibility even though reported debt has fallen to zero. Thin equity relative to the business scale increases sensitivity to funding needs, making the timing of commercialization and partnership monetization important to sustaining operations.
Partner And Regulatory Execution RiskImportant future revenues depend on regulatory progress and partners advancing programs on schedule, factors MedinCell does not fully control. Pathway changes or partner delays could defer launches, milestones and royalties, extending the period before the pipeline offsets current losses.
MedinCell SA News
0ACH FAQ
What was MedinCell SA’s price range in the past 12 months?
MedinCell SA lowest share price was €19.69 and its highest was €39.38 in the past 12 months.
What is MedinCell SA’s market cap?
MedinCell SA’s market cap is €802.47M.
When is MedinCell SA’s upcoming earnings report date?
MedinCell SA’s upcoming earnings report date is Dec 08, 2026 which is in 80 days.
How were MedinCell SA’s earnings last quarter?
MedinCell SA released its earnings results on Jun 16, 2026. The company reported -€0.45 earnings per share for the quarter, missing the consensus estimate of -€0.14 by -€0.31.
Is MedinCell SA overvalued?
According to Wall Street analysts MedinCell SA’s price is currently Undervalued.
Does MedinCell SA pay dividends?
MedinCell SA does not currently pay dividends.
What is MedinCell SA’s EPS estimate?
MedinCell SA’s EPS estimate is -0.22.
How many shares outstanding does MedinCell SA have?
MedinCell SA has 35,924,610 shares outstanding.
What happened to MedinCell SA’s price movement after its last earnings report?
MedinCell SA reported an EPS of -€0.45 in its last earnings report, missing expectations of -€0.14. Following the earnings report the stock price went up 0.216%.
Which hedge fund is a major shareholder of MedinCell SA?
Currently, no hedge funds are holding shares in GB:0ACH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedinCell SA
MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, presently in preclinical development. MedinCell is also actively engaged in formulation research for additional product candidates. These encompass subcutaneous injections such as mdc-WWM for contraception, mdc-ANG for central nervous system-related conditions, mdc-ELK for depression, and mdc-GRT for organ transplant applications. Furthermore, the firm is investigating perineural injections like mdc-CMV for anesthesia and pain management, and mdc-NVA, also intended for pain relief. MedinCell S.A. maintains its headquarters in Jacou, France.
0ACH Stock 12 Month Forecast
Average Price Target
€38.00
▲(55.36% Upside)